aMoon invests in $80m Adicet Bio financing round

Cancerous cells Photo: Shutterstock
Cancerous cells Photo: Shutterstock

Based on technology developed by the Technion's Prof. Yoram Reiter, Adicet Bio is developing allogeneic cell therapies for cancer using innovative gamma delta T cells.

US biopharmaceutical company Adicet Bio Inc. has raised $80 million in a Series B financing round. The money was raised from new investors including Marius Nacht and Dr. Yair Schindel's aMoon2 Fund. Dr. Schindel joins Adicet's board. Other new investors in the round were Regeneron Pharmaceuticals, Johnson & Johnson Innovation, OCI Enterprises, KB Investment, Consensus Business Group, SBI JI Innovation Fund, Samsung Venture Investment Corp, Handok, and DSC Investment. All existing investors including OrbiMed, Novartis Venture Fund and Pontifax also participated in the financing.

Based on technology developed by Prof. Yoram Reiter at the Technion Israel Institute of Technology in Haifa, Adicet Bio is developing allogeneic cell therapies for cancer using innovative gamma delta T cells.

aMoon head of sourcing Dr. Nurit Tweezer Zaks, who leds the investment on behalf of aMoon said, "In recent years CAR-T has made a revolution in the field of cancer. The principsal is that the cells in the immune system of the patient are tired and weak but if we take them out of the patient, and proliferate them in the laboratory in order to increase their magnitude very greatly and then put them back in the body, what we lack in quality we will have in quantity."

She added, "To this we can add a broad range of improvements like cell engineering to improve the ability to reach the target (as did Kyte Pharma, which was acquired by Gilead Pharmaceuticals for over $11 billion), characteristics that cause the cell only to work in a certain region, switches that facilitate operating or turning off the cell according to the area in which it is located, and more.

Adicet Bio CEO Dr. Anil Singhal said, "Gamma delta T cells are a highly promising, emerging modality for treating cancer. This financing will permit Adicet to continue to develop our proprietary technology, to enter the clinic in Non-Hodgkin's Lymphoma and to advance our solid tumor programs."

Published by Globes, Israel business news - en.globes.co.il - on October 3, 2019

© Copyright of Globes Publisher Itonut (1983) Ltd. 2019

Cancerous cells Photo: Shutterstock
Cancerous cells Photo: Shutterstock
groundcover founders credit: Yossi Yarom Israeli observability co groundcover raises $35m

groundcover has developed a “Bring Your Own Cloud” (BYOC) observability solution, redefining the architecture of a modern observability platform.

Tel Aviv Stock Exchange credit: Shutterstock MagioreStock Foreign investment in TASE hits five-year high

Foreign investors have been flocking to the Tel Aviv Stock Exchange in recent weeks, the TASE research department tells "Globes."

Elbit Systems tank turret systems credit: Elbit Systems Elbit Systems wins $100m tank turret systems deal

The Israel defense electronics company will supply its advanced UT30 MK2 unmanned turret systems to General Dynamics European Land Systems (GDELS) to be supplied to a NATO European country.

Tomer Weingarten Photo: PR Trump targets SentinelOne exec in act of revenge

The US administration has suspended the security clearance of the company's chef intelligence and public policy officer Chris Krebs and everyone associated with him.

Tel Aviv Stock Exchange share prices rising credit: Tali Bogdanovsky TASE opens sharply higher after Trump U-turn on tariffs

The pause is being interpreted as a climb down after US President Donald Trump admitted he had made the move to calm the markets.

Ashot Ashkelon credit: Ministry of Defense Up 250%, Ashot Ashkelon wins another Defense Ministry order

The Israeli defense company's share price has risen 250% in the past three years since FIMI Opportunity Funds acquired control.

Liad Agmon credit: Eyal Izhar Insight Partners Liad Agmon steps down as managing partner

Serial entrepreneur Agmon has served as a partner at Insight Partners Israel alongside Daniel Aronovitz who set up the Israel office.

Shekels credit: Shutterstock Vladerina32 Shekel slide resumes amid escalating tariff war

The Bank of Israel is not expected to intervene in the forex market despite the sharp depreciation of the shekel.

Nir Zuk credit: Inbal Marmari Palo Alto Networks mulls buying AI security co for $700m

Sources inform "Globes" that on Palo Alto's radar is Protect AI.

President Donald Trump hosts Prime Minister Benjamin Netanyahu credit: Reuters Kevin Mohatt Israeli officials confident on US tariff concessions

Senior Israeli figures believe that concessions could be tied to progress on strategic regional political issues that are important to President Trump.

Phoenix Investment House CEO Avner Hadad  credit: Tommy Harpaz "The market has priced in all the bad things"

Phoenix Investment House CEO Avner Hadad says US markets could continue to fall, but that we are close to interesting territory for patient investors.

Tel Aviv credit: Shutterstock Tel Aviv slips in World's Wealthiest Cities ranking

Tel Aviv's position as one of the world's wealthiest cities took a big knock over the past year as it slipped from 42nd to 48th in investment advisors Henley & Co.'s "World's Wealthiest Cities" Top 50 ranking.

Leviathan platform  credit: Albatross C'ttee seen recommending no cut in gas exports

The Dayan committee on the future of the gas sector estimates that Israel's natural gas reserves will run out in 2045.

Accountant General Yali Rothenberg credit: Rafi Kutz Israel's fiscal deficit continues to narrow

The deficit narrowed in the twelve months to the end of March 2025, for the sixth consecutive month, Ministry of Finance accountant general Yali Rothenberg reported today.

Arkia credit: Arkia Arkia cuts Tel Aviv - New York April fares

Arkia has cut fares at the last minute, a time when prices usually soar even higher, according to the pricing method used in the industry.

Bank of Israel Governor Prof. Amir Yaron credit: Dani Shem Tov Knesset Spokesperson BoI Governor: US tariffs could push up inflation in Israel

Prof. Amir Yaron tells "Globes" that there is a risk that the new tariffs will cause inflation to rise in the US, with a knock-on effect for Israel.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018